Skip to main content

Advertisement

SpringerLink
Log in

Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Several rheumatic diseases have a perplexing association with cancer. Unraveling this mysterious connection is likely to provide deeper understanding regarding mechanisms governing the onset of both autoimmunity and cancer immunity, in addition to providing clinicians much needed guidance around whom and when to screen for occult malignancy. Systemic sclerosis (scleroderma) and dermatomyositis are two diseases in which the association with internal malignancy is well-described and can be considered as models from which to gain important insights that likely have broader applicability. The past 15 years have witnessed a striking acceleration in understanding how these two diseases are related to cancer emergence–an important crack in this inscrutable armor has been the discovery and characterization of disease-specific autoantigens that are closely tied with risk of cancer emergence. The best-described examples of this are antibodies against anti-RNA polymerase III (anti-POL3) and transcription intermediary factor 1-gamma (anti-TIF1γ). Patients with systemic sclerosis and cancer that are diagnosed within a short time interval of each other frequently have anti-POL3 antibodies. Antibodies against the minor spliceosome protein RNA-Binding Region Containing 3 (RNPC3) are also associated with increased cancer incidence in systemic sclerosis. Similarly, in the dermatomyositis spectrum, the majority of anti-TIF1γ-associated cancers are detected around the time of DM onset (most often within 1 year). Antibodies against Nuclear Matrix Protein 2 are also potentially associated with increased cancer emergence in dermatomyositis. The systemic sclerosis/anti-POL3 connection with close cancer onset led to the first experiments directly supporting the concept that rheumatic disease may in fact be a manifestation of cancer. It is now clear that studying these diseases through the lens of autoantibodies can reveal relationships and insights that would otherwise remain obscured. Extending these studies, new findings show that antibodies against RNA polymerase I large subunit are associated with protection against short interval cancers in anti-POL3-positive systemic sclerosis patients. These insights highlight the fact that autoantigen discovery related to cancer emergence remains an important priority; such new tools will enable the testing of specific hypotheses regarding mechanisms governing disease emergence and development of effective anti-tumor responses. Autoantibody phenotype will likely play an important role in the development of cancer screening guidelines that are critically needed by clinicians taking care of these patients. In this review, we will summarize the current state of knowledge regarding the different ways in which autoantibodies are connected with systemic sclerosis/dermatomyositis and malignancy and highlight potential paths forward.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152–157

    Article  CAS  PubMed  Google Scholar 

  2. Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L (2019) Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clin Exp Rheumatol 37(6):1048–1051

    PubMed  PubMed Central  Google Scholar 

  3. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A (2013) Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52(1):143–154

    Article  Google Scholar 

  4. Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65(7):1913–1921

    Article  PubMed  Google Scholar 

  5. Morrisroe K, Nikpour M (2020) Cancer and scleroderma: recent insights. Curr Opin Rheumatol 32(6):479–487

    Article  PubMed  Google Scholar 

  6. Maria ATJ, Partouche L, Goulabchand R, Riviere S, Rozier P, Bourgier C, Le Quellec A, Morel J, Noel D, Guilpain P (2018) Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors. Front Immunol 9:3112

    Article  CAS  PubMed  Google Scholar 

  7. Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67(2):317–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16(1):R53

    Article  PubMed  PubMed Central  Google Scholar 

  9. Colaci M, Giuggioli D, Vacchi C, Lumetti F, Iachetta F, Marcheselli L, Federico M, Ferri C (2014) Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 13(2):132–137

    Article  PubMed  Google Scholar 

  10. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62(9):2787–2795

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W (2011) Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 13(6):R211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F (2011) Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38(7):1329–1334

    Article  CAS  PubMed  Google Scholar 

  13. Aozasa N, Miyazaki M, Hayakawa J, Tamaki T, Hamaguchi Y, Sato S, Asano Y (2020) Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation. J Dermatol 47(7):e269–e270

    Article  PubMed  Google Scholar 

  14. Xu GJ, Shah AA, Li MZ, Xu Q, Rosen A, Casciola-Rosen L, Elledge SJ (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci USA 113(47):E7526–E7534

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L (2017) Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol 69(6):1306–1312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K (2017) Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin Exp Rheumatol 35(Suppl 106):71–74

    PubMed  PubMed Central  Google Scholar 

  17. Betteridge ZE, Priest L, Cooper RG, McHugh NJ, Blackhall F, Lamb JA (2018) Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. Arthritis Res Ther 20(1):176

    Article  PubMed  PubMed Central  Google Scholar 

  18. Partouche L, Goulabchand R, Maria ATJ, Riviere S, Jorgensen C, Rigau V, Bourgier C, Bessis D, Le Quellec A, Quere I, Morel J, Guilpain P (2020) Biphasic temporal relationship between cancers and systemic sclerosis: a clinical series from Montpellier University Hospital and review of the literature. J Clin Med 9(3):853

    Article  PubMed Central  Google Scholar 

  19. Shah AA, Laiho M, Rosen A, Casciola-Rosen L (2019) Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma. Arthritis Rheumatol 71(9):1571–1579

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Shah AA, Rosen A (2011) Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 23(6):530–535

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mecoli CA, Adler BL, Yang Q, Hummers LK, Rosen A, Casciola-Rosen L, Shah AA (2021) Cancer in systemic sclerosis: analysis of antibodies against components of the Th/To complex. Arthritis Rheumatol 73(2):315–323

    Article  CAS  PubMed  Google Scholar 

  22. Watad A, McGonagle D, Bragazzi NL, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (2019) Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. Oncoimmunology 8(6):e1588084

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 67(4):1053–1061

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, Rosen A, Shah AA (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77(8):1179–1186

    PubMed  Google Scholar 

  25. Stertz G (1916) Polymyositis. Berl Klin Wochenschr 53:489

    Google Scholar 

  26. Kankeleit H (1916) Über primaire nichteitrige polymyositis. Dtsch Arch Klin Med 120:335–339

    Google Scholar 

  27. Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300–1303

    CAS  PubMed  Google Scholar 

  28. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6(1):9–13

    Article  CAS  PubMed  Google Scholar 

  29. Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis: A population-based study. N Engl J Med 326(6):363–367

    Article  CAS  PubMed  Google Scholar 

  30. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100

    Article  CAS  PubMed  Google Scholar 

  31. Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21(2):131–136

    Article  PubMed  Google Scholar 

  32. Di Rollo D, Abeni D, Tracanna M, Capo A, Amerio P (2014) Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol 149(5):525–537

    PubMed  Google Scholar 

  33. Madan V, Chinoy H, Griffiths CE, Cooper RG (2009) Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 34(4):451–455

    Article  CAS  PubMed  Google Scholar 

  34. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70(6):360–374

    Article  CAS  Google Scholar 

  35. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46(1):25–28

    Article  CAS  PubMed  Google Scholar 

  37. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, Miller FW, Rider LG (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689

    Article  CAS  PubMed  Google Scholar 

  38. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64(2):513–522

    Article  CAS  PubMed  Google Scholar 

  39. Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D (2019) Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol 99(3):256–262

    Article  CAS  PubMed  Google Scholar 

  40. Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H, UkmyoNet (2019) The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58(4):650–655

    Article  Google Scholar 

  41. Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Kono M, Akiyama M (2018) Strong correlation between cancer progression and anti-transcription intermediary factor 1gamma antibodies in dermatomyositis patients. Clin Exp Rheumatol 36(6):990–995

    PubMed  Google Scholar 

  42. Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259

    Article  PubMed  PubMed Central  Google Scholar 

  43. Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 69(11):1771–1776

    Article  CAS  Google Scholar 

  44. Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N, contributors UK (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, Martel C, Masseau A, Meyer A, Terrier B, Guegan S, Verneuil L, Audia S, Livideanu CB, Hachulla E, Kahn JE, Lefevre G, Maurier F, Moulis G, Papo T, Dossier A, Descamps V, Salort-Campana E, Richard MA, Bergot E, Mortier L, Costedoat-Chalumeau N, Genot S, Perez F, Piette AM, Samson M, Schleinitz N, Zenone T, Lacoste M, de Boysson H, Madaule S, Rigolet A, Champtiaux N, Hervier B, Bouvier AM, Jooste V, Leonard-Louis S, Maisonobe T, Aouba A, Benveniste O, Bienvenu B, Allenbach Y, French Myositis N (2020) Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 83(6):1759–1763

    Article  CAS  PubMed  Google Scholar 

  46. Zhang YM, Liang L, Yang HB, Shu XM, Lu X, Wang GC, Peng QL (2020) Identification of a novel autoantibody against heat shock factor 1 in idiopathic inflammatory myopathy. Clin Exp Rheumatol 38(6):1191–1200

    PubMed  Google Scholar 

  47. Chen H, Yang H, Cheng QX, Ge YP, Peng QL, Zhang YM, Cheng GH, Wang GC, Lu X (2020) A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies. Clin Transl Immunology 9(10):e1195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Motegi SI, Sekiguchi A, Ikeuchi H, Sakairi T, Ogawa H, Fujii T, Sohda M, Yajima T, Ida S, Takayasu Y, Shimoda Y, Hiromura K, Saeki H, Shirabe K, Chikamatsu K, Yokoo H, Oyama T, Ishikawa O (2020) Clinical features of anti-transcription intermediary factor 1gamma (TIF1gamma)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1gamma expression in tumors in the pathogenesis of cancer-associated dermatomyositis. J Dermatol 47(12):1395–1402

    Article  CAS  PubMed  Google Scholar 

  49. Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martinez MA, Milisenda JC, Aparicio-Espanol G, Labrador-Horrillo M, Garcia-Patos V, Grau-Junyent JM, Selva-O’Callaghan A (2018) Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford) 57(2):388–396

    Article  CAS  Google Scholar 

  50. Cordel N, Derambure C, Coutant S, Mariette X, Jullien D, Debarbieux S, Chosidow O, Meyer A, Bessis D, Joly P, Mathian A, Levesque H, Sabourin JC, Tournier I, Boyer O, OncoMyositis Study group (2021) TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1gamma positive cancer-associated dermatomyositis. Rheumatology (Oxford) 60(12):5863–5867

    Article  CAS  Google Scholar 

  51. Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T, Aihara M (2020) Clinical significance of serum levels of anti-transcriptional intermediary factor 1-gamma antibody in patients with dermatomyositis. J Dermatol 47(5):490–496

    Article  CAS  PubMed  Google Scholar 

  52. Pan J, Yu L, Wu Q, Lin X, Liu S, Hu S, Rosa C, Eichinger D, Pino I, Zhu H, Qian J, Huang Y (2020) Integration of IgA and IgG autoantigens improves performance of biomarker panels for early diagnosis of lung cancer. Mol Cell Proteomics 19(3):490–500

    Article  PubMed  PubMed Central  Google Scholar 

  53. Chen M, Lin X, Zhang L, Yu L, Wu Q, Zhang S, Xue F, Huang Y (2020) Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer. Int J Med Sci 17(17):2744–2750

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Venalis P, Selickaja S, Lundberg K, Rugiene R, Lundberg IE (2018) Association of anti-transcription intermediary factor 1gamma antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis. Arthritis Care Res (Hoboken) 70(4):648–651

    Article  CAS  Google Scholar 

  55. Vazquez-Del Mercado M, Martinez-Garcia EA, Daneri-Navarro A, Gomez-Banuelos E, Martin-Marquez BT, Pizano-Martinez O, Wilson-Manriquez EA, Corona-Sanchez EG, Chavarria-Avila E, Sandoval-Garcia F, Satoh M (2021) Presence of anti-TIF-1gamma, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study. Immunopharmacol Immunotoxicol 43(3):328–333

    Article  CAS  PubMed  Google Scholar 

  56. Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW (2016) Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford) 55(9):1631–1641

    Article  CAS  Google Scholar 

  57. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 65(11):2954–2962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Oya K, Inoue S, Saito A, Nakamura Y, Ishitsuka Y, Fujisawa Y, Watanabe R, Taguchi S, Fujimoto M, Okiyama N (2020) Pregnancy triggers the onset of anti-transcriptional intermediary factor 1gamma antibody-positive dermatomyositis: a case series. Rheumatology (Oxford) 59(6):1450–1451

    Article  CAS  Google Scholar 

  59. Oldroyd AGS, Allard AB, Callen JP, Chinoy H, Chung L, Fiorentino D, George MD, Gordon P, Kolstad K, Kurtzman DJB, Machado PM, McHugh NJ, Postolova A, Selva-O’Callaghan A, Schmidt J, Tansley S, Vleugels RA, Werth VP, Aggarwal R (2021) A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford) 60(6):2615–2628

    Article  CAS  Google Scholar 

  60. Jia E, Wei J, Geng H, Qiu X, Xie J, Xiao Y, Zhong L, Xiao M, Zhang Y, Jiang Y, Zhang J (2019) Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review. Clin Rheumatol 38(8):2189–2193

    Article  PubMed  Google Scholar 

  61. Aussy A, Freret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Fabienne J, Joly P, Isabelle M, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Hue S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O, OncoMyositis Study Group (2019) The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol 71(8):1360–1370

    Article  CAS  PubMed  Google Scholar 

  62. Jorgovanovic D, Song M, Wang L, Zhang Y (2020) Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res 8:49

    Article  PubMed  PubMed Central  Google Scholar 

  63. Selva-O’Callaghan A, Grau JM, Gamez-Cenzano C, Vidaller-Palacin A, Martinez-Gomez X, Trallero-Araguas E, Andia-Navarro E, Vilardell-Tarres M (2010) Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 123(6):558–562

    Article  PubMed  Google Scholar 

  64. Li X, Tan H (2020) Value of (18)F-FDG PET/CT in the detection of occult malignancy in patients with dermatomyositis. Heliyon 6(4):e03707

    Article  PubMed  PubMed Central  Google Scholar 

  65. Kundrick A, Kirby J, Ba D, Leslie D, Olsen N, Foulke G (2019) Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum 49(1):140–144

    Article  PubMed  Google Scholar 

  66. Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R (2020) Risk factors and cancer screening in myositis. Rheum Dis Clin North Am 46(3):565–576

    Article  PubMed  Google Scholar 

  67. Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D (2018) Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore) 97(2):e9639

    Article  Google Scholar 

  68. Sparsa A, Liozon E, Herrmann F, Ly K, Lebrun V, Soria P, Loustaud-Ratti V, Bouyssou-Gauthier ML, Boulinguez S, Bedane C, Jauberteau MO, Vidal E, Bonnetblanc JM (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138(7):885–890

    Article  PubMed  Google Scholar 

  69. Khanna U, Galimberti F, Li Y, Fernandez AP (2021) Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening? Ann Transl Med 9(5):432

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

LCR was funded in part by the National Institutes of Health (RO1 AR073208) and the Donald B. and Dorothy L. Stabler Foundation.

Author information

Authors and Affiliations

  1. Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA

    David F. Fiorentino

  2. Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Livia Casciola-Rosen

Authors
  1. David F. Fiorentino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Livia Casciola-Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DFF and LCR both devised the structure and content of this article, as well as performing literature searches, drafting of the manuscript, and critical revision.

Corresponding author

Correspondence to Livia Casciola-Rosen.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fiorentino, D.F., Casciola-Rosen, L. Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis. Clinic Rev Allerg Immunol 63, 330–341 (2022). https://doi.org/10.1007/s12016-022-08944-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-022-08944-y

Keywords

Search

Navigation